[理想树]2025年普通高等学校招生全国统一考试高考临考卷英语A卷答案正在持续更新，目前2026金太阳答案网为大家整理了相关试题及答案，供大家查缺补漏，高效提升成绩。

DWhen Genentech, a highly influential Swedish medical company, got the license forthe lung-treating medicine Vixarelimab from another company, Artificial Intelligence(AI) brought an unexpected discovery: the drug could also be effective in treatinginflammatory bowel disease. This vividly shows the amazing potential of AI in the field of drug research and development( R&D).The application of AI in the industry is on an upward tendency. Data(数据) fromthe Boston Consulting Group shows the number of clinical(临床的） experiments using AIin finding and designing molecules—the key stages of drug R&D—-has jumped to 67 in2023 from only 27 in 2021. AstraZeneca, British drug giant, is a good example of AI'sinfluence. The company used AI to cut the time for molecule design from years to justmonths or even weeks. Similarly, London-based GSK has recognized the potential of AIacross its entire R&D process.However, the path to fully integrating AI into medical R&D is anything but even."There is a data problem, a people problem and a bit of a strategy problem," saidThomas Clozel, CEO and co-founder of Owkin, a Paris-based company that applies AIto medical research. Acquiring data and AI skills is among the key factors medicalcompanies’ focus on short-term results and their difficulties in attracting and keepingdata scientists influence the industry's embrace of AI.To overcome these problems, medical companies are forming partnerships with AIexperts to employ AI technology in their operations. Eli Lilly, Moderna, and Sanofihave joined forces with ChatGPT's developer, OpenAI. Meanwhile, Novartis and EliLilly have teamed up with Isomorphic Labs, a company founded and led by Nobel Prizewinner Demis Hassabis and owned by Alphabet. While the application of AI in this fieldis still at its early stage and may take years to fully realize its potential, medicalcompanies are highly keen to improve the long and costly drug-development process withAI, finally leading to more efficient and effective drug discoveries.32. According to the article, what did AI discover about Vixarelimab?A. Vixarelimab got the license for drug R&D. B. Vixarelimab is ineffective for lung diseases.C. Vixarelimab has an amazing potential to influence AI.D. Vixarelimab can treat another disease besides lung problems.33. What can we infer from the change of clinical experiments with AI?A. Medical companies are losing interest in AI.B. AI has not shown advantages in clinical experiments as expected.C. The application of AI in the medical industry is becoming increasingly popular.D. AI has replaced the traditional methods in drug development.34. What does the underlined sentence in paragraph 3 suggest?S p d s s on sB. The process of using AI in medical R&D is smooth.C. The problems in embracing AI are even bigger for medical industry.D. The journey of applying AI to medical industry is filled with challenges.高一英语试题第6页(共10页)夸克扫描王极速扫描，就是高效